Skip to main content
Erschienen in: Der Gynäkologe 2/2015

01.02.2015 | Leitthema

Rheumatologische Erkrankungen in der Schwangerschaft

verfasst von: A. von Figura, S. Patschan, N. Bock, Prof. Dr. G.A. Müller

Erschienen in: Die Gynäkologie | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Rheumatische Erkrankungen in der Schwangerschaft haben Einfluss auf maternale sowie fetale Morbidität und Mortalität. Umgekehrt kann eine Schwangerschaft die rheumatische Erkrankung beeinflussen: Während sich die rheumatoide Arthritis während der Schwangerschaft häufig bessert, müssen Frauen mit Lupus erythematodes oder ankylosierender Spondylitis mit vermehrten Schüben ihrer Grunderkrankung rechnen. Die präkonzeptionelle interdisziplinäre Beratung der Frauen ist entscheidend. Eine individuelle, interdisziplinäre Therapie der Frau, die die Auswirkungen auf Fetus und Kind beachtet, sollte an einem Perinatalzentrum Level I erfolgen.
Literatur
1.
Zurück zum Zitat Wallenius M, Skomsvoll JF, Irgens LM et al (2010) Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry. Ann Rheum Dis 69:332–336CrossRefPubMed Wallenius M, Skomsvoll JF, Irgens LM et al (2010) Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry. Ann Rheum Dis 69:332–336CrossRefPubMed
2.
Zurück zum Zitat Jahaweer D, Zhu JL, Nohr EA, Olsen J (2011) Time to pregnancy among woman with rheumatoid arthritis. Arthritis Rheum 63:1517–1521CrossRef Jahaweer D, Zhu JL, Nohr EA, Olsen J (2011) Time to pregnancy among woman with rheumatoid arthritis. Arthritis Rheum 63:1517–1521CrossRef
3.
Zurück zum Zitat Man YA de, Dolhain RJ, Geijn FE van de et al (2009) Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 60:3196–3206CrossRefPubMed Man YA de, Dolhain RJ, Geijn FE van de et al (2009) Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 60:3196–3206CrossRefPubMed
4.
Zurück zum Zitat Chakravarty EF, Nelson L, Krishnan E (2006) Obstetric hospitalizations in the United States for woman with systemic lupus erythematodes and rheumatoid arthritis. Arthritis Rheum 54(3):899–907CrossRefPubMed Chakravarty EF, Nelson L, Krishnan E (2006) Obstetric hospitalizations in the United States for woman with systemic lupus erythematodes and rheumatoid arthritis. Arthritis Rheum 54(3):899–907CrossRefPubMed
5.
Zurück zum Zitat Fischer-Betz R (2012) Rheumatische Erkrankungen in der Schwangerschaft. Internist 53:1047–1053CrossRefPubMed Fischer-Betz R (2012) Rheumatische Erkrankungen in der Schwangerschaft. Internist 53:1047–1053CrossRefPubMed
6.
Zurück zum Zitat Ostensen M, Ostensen H (1998) Ankylosing spondylitis – the female aspect. J Rheumatol 25:120–124PubMed Ostensen M, Ostensen H (1998) Ankylosing spondylitis – the female aspect. J Rheumatol 25:120–124PubMed
7.
Zurück zum Zitat Lui NL, Haroon N, Carty A et al (2011) Effect of pregnancy on ankylosing spondylitis: a case-control study. J Rheumatol 38:2442–2444CrossRefPubMed Lui NL, Haroon N, Carty A et al (2011) Effect of pregnancy on ankylosing spondylitis: a case-control study. J Rheumatol 38:2442–2444CrossRefPubMed
8.
Zurück zum Zitat Ostensen M, Fuhrer L, Mathieu R et al (2004) A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 63:1212–1217CrossRefPubMedPubMedCentral Ostensen M, Fuhrer L, Mathieu R et al (2004) A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 63:1212–1217CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Clowse ME, Magder LS, Witter F et al (2005) The impact of increased lupus activity on obstretric outcomes. Arthritis Rheum 52:514–521CrossRefPubMed Clowse ME, Magder LS, Witter F et al (2005) The impact of increased lupus activity on obstretric outcomes. Arthritis Rheum 52:514–521CrossRefPubMed
11.
Zurück zum Zitat Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54(11):3640–3647CrossRefPubMed Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54(11):3640–3647CrossRefPubMed
12.
Zurück zum Zitat Georgiou PE, Politi EN, Katsimbri P et al (2000) Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford) 39(9):1014–1019 Georgiou PE, Politi EN, Katsimbri P et al (2000) Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford) 39(9):1014–1019
13.
Zurück zum Zitat Petri M, Allbritton J (1993) Fetal outcome of lupus pregnancy: a retrospective case-control study of Hopkins Lupus Cohort. J Rheumatol 20:650–656PubMed Petri M, Allbritton J (1993) Fetal outcome of lupus pregnancy: a retrospective case-control study of Hopkins Lupus Cohort. J Rheumatol 20:650–656PubMed
14.
Zurück zum Zitat Clark CA, Spitzer KA, Laskin CA (2005) Decrease in pregnancy loss rates in patients with systemic lupus erythematodes over a 40-yera period. J Rheumatol 32:1709–1712PubMed Clark CA, Spitzer KA, Laskin CA (2005) Decrease in pregnancy loss rates in patients with systemic lupus erythematodes over a 40-yera period. J Rheumatol 32:1709–1712PubMed
15.
Zurück zum Zitat Clowse ME, Magder LS, Witter F, Petri M (2006) Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107(2 Pt 1):293–299CrossRefPubMed Clowse ME, Magder LS, Witter F, Petri M (2006) Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107(2 Pt 1):293–299CrossRefPubMed
16.
Zurück zum Zitat Chakravarty EF, Nelson L, Krishnan E (2005) Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 192:1897–1904CrossRefPubMed Chakravarty EF, Nelson L, Krishnan E (2005) Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 192:1897–1904CrossRefPubMed
17.
18.
Zurück zum Zitat Moroni G, Ponticelli C (2003) The risk of pregnancy in patients with lupus nephritis. J Nephrol 16(2):161–167PubMed Moroni G, Ponticelli C (2003) The risk of pregnancy in patients with lupus nephritis. J Nephrol 16(2):161–167PubMed
19.
Zurück zum Zitat Qazi UM, Petri M (2006) Autoantibodies, low complement, and obesity predict preeclampsia in SLE: a case-control study. Arthritis Rheum 54(9 Suppl):S264CrossRef Qazi UM, Petri M (2006) Autoantibodies, low complement, and obesity predict preeclampsia in SLE: a case-control study. Arthritis Rheum 54(9 Suppl):S264CrossRef
20.
Zurück zum Zitat Smyth A, Oliveira GH, Lahr BD et al (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythemtaodes and lupus nephritis. Clin J Am Soc Nephrol 5:2060–2068CrossRefPubMedPubMedCentral Smyth A, Oliveira GH, Lahr BD et al (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythemtaodes and lupus nephritis. Clin J Am Soc Nephrol 5:2060–2068CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Day CJ, Lipkin GW, Savage CO (2009) Lupus nephritis and pregnancy in the 21st century. Nephrol Dial Transplant 24:344–347CrossRefPubMed Day CJ, Lipkin GW, Savage CO (2009) Lupus nephritis and pregnancy in the 21st century. Nephrol Dial Transplant 24:344–347CrossRefPubMed
22.
Zurück zum Zitat Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205CrossRefPubMed Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205CrossRefPubMed
23.
Zurück zum Zitat Mok CC, Tang S, To C, Metri M (2005) Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 52:2774–2782CrossRefPubMed Mok CC, Tang S, To C, Metri M (2005) Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 52:2774–2782CrossRefPubMed
24.
Zurück zum Zitat Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376:1498–1509CrossRefPubMed Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376:1498–1509CrossRefPubMed
25.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed
26.
Zurück zum Zitat Ruffatti A, Tonello M, Del Ross T et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnany morbidity. Thromb Haemost 96:337–341PubMed Ruffatti A, Tonello M, Del Ross T et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnany morbidity. Thromb Haemost 96:337–341PubMed
27.
Zurück zum Zitat Ruffatti A, Tonello M, Cavazzana A et al (2009) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123:482–487CrossRefPubMed Ruffatti A, Tonello M, Cavazzana A et al (2009) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123:482–487CrossRefPubMed
28.
Zurück zum Zitat Ruffatti A, Tonello M, Visenti MS et al (2011) Risk factors for pregnancy failure in patients with antiphospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 50:1684–1689 Ruffatti A, Tonello M, Visenti MS et al (2011) Risk factors for pregnancy failure in patients with antiphospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 50:1684–1689
29.
Zurück zum Zitat Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64CrossRefPubMed Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64CrossRefPubMed
30.
Zurück zum Zitat Danowski A, Azevedo MN de, Souza Papi JA de, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199CrossRefPubMed Danowski A, Azevedo MN de, Souza Papi JA de, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199CrossRefPubMed
31.
Zurück zum Zitat Izmirly PM, Rivera TL, Buyon JP (2007) Neonatal lupus syndromes. Rheum Dis Clin North Am 33:267–285CrossRefPubMed Izmirly PM, Rivera TL, Buyon JP (2007) Neonatal lupus syndromes. Rheum Dis Clin North Am 33:267–285CrossRefPubMed
32.
Zurück zum Zitat Saleeb S, Copel J, Friedman D, Buyon JP (1999) Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 42:2335–2345CrossRefPubMed Saleeb S, Copel J, Friedman D, Buyon JP (1999) Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 42:2335–2345CrossRefPubMed
33.
Zurück zum Zitat Rein AJ, Mevorach D, Perles Z et al (1999) Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogramm-based study. Circulation 119:1867–1872CrossRef Rein AJ, Mevorach D, Perles Z et al (1999) Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogramm-based study. Circulation 119:1867–1872CrossRef
34.
Zurück zum Zitat Jaeggi ET, Fouron JC, Silverman ED et al (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110:1542–1548CrossRefPubMed Jaeggi ET, Fouron JC, Silverman ED et al (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110:1542–1548CrossRefPubMed
35.
Zurück zum Zitat Izmirly PM, Saxena A, Kim MY et al (2010) Evaluation of the risk of anti-SSA/Ro-SSB/La-antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 69:1827–1830CrossRefPubMedPubMedCentral Izmirly PM, Saxena A, Kim MY et al (2010) Evaluation of the risk of anti-SSA/Ro-SSB/La-antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 69:1827–1830CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Izmirly PM, Saxena A, Kim MY et al (2011) Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124:1927–1935CrossRefPubMedPubMedCentral Izmirly PM, Saxena A, Kim MY et al (2011) Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124:1927–1935CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Fischer-Betz RE, Gromnica-Ihle E (2010) Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 69:633–641CrossRefPubMed Fischer-Betz RE, Gromnica-Ihle E (2010) Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 69:633–641CrossRefPubMed
38.
Zurück zum Zitat Gerosa M, Meroni PL, Cimaz R (2014) Safety considerations when prescribing immunpsuppression medication to pregnant woman. Expert Opin Drug Saf 5:1–9 Gerosa M, Meroni PL, Cimaz R (2014) Safety considerations when prescribing immunpsuppression medication to pregnant woman. Expert Opin Drug Saf 5:1–9
Metadaten
Titel
Rheumatologische Erkrankungen in der Schwangerschaft
verfasst von
A. von Figura
S. Patschan
N. Bock
Prof. Dr. G.A. Müller
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gynäkologie / Ausgabe 2/2015
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-014-3411-3

Weitere Artikel der Ausgabe 2/2015

Der Gynäkologe 2/2015 Zur Ausgabe

Magazinseite

Magazin

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.